Biotech

All Articles

Bivictrix makes a decision going exclusive only technique to take ADC in to center

.Antibody-drug conjugates (ADCs) have actually been at the center of many a billion-dollar biobuck l...

TPG bests up funds to $580M for investments throughout lifestyle sciences

.Asset manager TPG, which has sustained biotechs including Sionna Therapeutics and Santa Ana Bio, ha...

Merck quits period 3 TIGIT test in bronchi cancer cells for impossibility

.Merck &amp Co.'s TIGIT program has actually gone through one more setback. Months after shuttering ...

After a challenging year, Exscientia folds right into Recursion

.After a year defined by pipe cuts, the variation of its chief executive officer and layoffs, Exscie...

Cullinan, after $25M offer, return bispecific to Port

.Cullinan Therapy was made an impression on good enough with Harbour BioMed's bispecific immune acti...

A better take a look at Brutal Biotech's Ferocious 15

.In this week's incident of "The Best Line," our experts're diving into Tough Biotech's annual Tough...

Lilly experiences phase 2 failure of tau-targeting med

.The confetti is actually still flying from Eli Lilly's celebration commemorating the approval of Al...

Biogen CMO Maha Radhakrishnan joins Sofinnova-- Chutes &amp Ladders

.Welcome to today's Chutes &amp Ladders, our roundup of notable leadership hirings, shootings as wel...

Lykos will certainly ask FDA to rethink its choice observing rejection of MDMA therapy for post-traumatic stress disorder

.Following a poor showing for Lykos Therapeutics' MDMA candidate for trauma at a current FDA advisor...

AN 2 halves headcount, quits period 3 trial after records disappoint

.AN2 Therapeutics is actually reassessing its organization in action to dull midphase data, swearing...